The Download: GLP-1s and eating disorders, self-aware cities, and forever chemicals

MIT Technology Review’s latest newsletter, “The Download,” focuses on the clinical and societal implications of GLP‑1 weight‑loss drugs, such as semaglutide (Ozempic) and tirzepatide (Mounjaro). The article highlights emerging evidence that these medications can trigger or worsen eating disorders, especially in vulnerable populations. It also touches on other topics—self‑aware smart city infrastructure and persistent per- and polyfluoroalkyl substances (PFAS)—but the primary concern for enterprise IT is the healthcare data and regulatory environment surrounding GLP‑1 therapy.

Why it matters for enterprise IT teams: 1. **Data Governance**: Patient records containing GLP‑1 prescriptions must be handled under strict privacy laws (UK GDPR, HIPAA). The newsletter notes that insurers and employers are increasingly requesting detailed claims data to monitor drug usage patterns, raising questions about data access, de‑identification, and consent. 2. **System Integration**: Many hospitals use disparate EHR systems (Epic, Cerner, Allscripts). Integrating GLP‑1 usage data with workforce health platforms requires secure APIs, consistent data models, and real‑time analytics. 3. **Compliance & Auditing**: The risk of inadvertently exposing sensitive health information or failing to meet audit requirements is high. Enterprise IT must ensure that data flows comply with GDPR’s “right to be forgotten” and data minimization principles. 4. **Vendor Landscape**: Health analytics vendors (SAS, Optum, Evidian) are developing modules to flag potential eating disorder indicators. Cloud platforms (AWS HealthLake, Azure Health Data Services) are offering HIPAA‑compliant data lakes for aggregated drug‑use analytics.

Broader industry implications: - **Insurance & Payroll**: Employers may use GLP‑1 data to adjust wellness program incentives, potentially leading to discrimination claims. - **Regulatory Scrutiny**: The FDA and MHRA are reviewing post‑marketing safety signals, which could trigger mandatory reporting requirements for IT systems that store or process prescription data. - **Data Monetization**: Vendors offering predictive analytics on drug‑related health outcomes could create new revenue streams, but also new compliance burdens.

Enterprise IT must therefore prepare for tighter data controls, new integration points, and evolving regulatory expectations as GLP‑1 drugs become mainstream.